Trial Profile

A Phase Ia Trial of ATI-2231 in Advanced Solid Tumor Malignancies

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 01 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATI 2231 (Primary) ; Capecitabine (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Gastrointestinal cancer; Head and neck cancer; HER2 negative breast cancer; Male breast cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man

Most Recent Events

28 Nov 2023 Planned initiation date changed from 30 Nov 2023 to 15 Nov 2023.
28 Nov 2023 Status changed from suspended to withdrawn prior to enrolment.
16 Nov 2023 Status changed from not yet recruiting to suspended.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com